DUBLIN, May 13, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/42hpkb/nontyrosine) has announced the addition of the "Non-Tyrosine Kinase Inhibitors in Oncology, 2015 - 2025" report to their offering. 

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Apart from the bigger pharmaceutical companies such as Roche/Genentech, Eli Lilly, Novartis, Pfizer, AstraZeneca, several smaller/ start-up companies have shown their participation in this area. As the industry gains momentum, many companies have already benefitted by adopting the strategy of discovering the compounds and then out-licensing to bigger companies. 

The Non-Tyrosine Kinase Inhibitors in Oncology, 2015-2025 report provides a comprehensive analysis of the current market landscape and the future outlook of kinase inhibitors not specifically targeting tyrosine kinases. These include kinase inhibitors with activity against serine/threonine kinases, dual specificity kinases or both tyrosine and serine/threonine kinases being developed for oncological indications. Targeted therapy, specifically small molecule protein kinase inhibitors, has emerged as the new generation of cancer treatment that specifically targets only cancer cells. Although the market of protein kinase inhibitors is dominated by tyrosine kinase inhibitors, non-tyrosine kinase inhibitors (serine/threonine kinase inhibitors, dual specificity kinase inhibitors and drugs that inhibit both tyrosine and serine/threonine kinases) have gained a significant momentum in the last few years. 

There are total seven marketed non-tyrosine kinase inhibitors approved so far. Nexavar, the first drug of this type, received approval in 2005. Subsequently, Torisel (2007), Afinitor (2009), Zelboraf (2011), Tafinlar (2013), Mekinist (2013) and Ibrance (2015) were approved. The pipeline is rich and holds a significant potential for future. 

Most of the non-tyrosine kinase inhibitors identified during our research target mTOR, CDK, RAF and MEK kinases. In addition, there are several novel non-tyrosine kinase inhibitors under development that target other serine/threonine and dual specificity kinases (e.g. PLK1, ERK, PIM, Chk kinases). 

Key Topics Covered: 

1. Preface 

2. Executive Summary 

3. Cancer Therapeutics and Targeted Cancer Therapy 

4. Non-Tyrosine Kinase Inhibitors: Current Market Landscape 

5. mTOR Inhibitors: Key Molecules and Future Outlook 

6. Cdk Inhibitors: Key Molecules and Future Outlook 

7. RAF / MEK Inhibitors: Key Molecules and Future Outlook 

8. Novel Non-Tyrosine Kinase Inhibitors: Key Molecules and Future Outlook 

9. Company Profiles 

10. Interview Transcripts 

11. Conclusion 

12. Appendix 1: Tabulated Data 

13. Appendix 2: List of Companies and Organizations 

Companies Profiles 

• Roche
• Eli Lilly
• Novartis
• Array BioPharma
• Nerviano Medical Sciences
• Cyclacel Pharmaceuticals
• Daiichi Sankyo
• Onconova Therapeutics
• AstraZeneca
• GlaxoSmithKline (GSK)
• Pfizer
• Merck KGaA
• Astex Pharmaceuticals
• Carna Biosciences
• Celgene Corporation
• Non-Tyrosine Kinase Inhibitors Pipeline
• Eternity Bioscience

For more information visit http://www.researchandmarkets.com/research/42hpkb/nontyrosine

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets